Acadia Pharma (ACAD) Misses Q1 EPS by 13c

Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.40), $0.13 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Jernigan Capital (JCAP) Tops Q2 EPS by 5c